StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a research report sent to investors on Sunday morning. The firm issued a sell rating on the stock.
Ayala Pharmaceuticals Price Performance
Shares of ADXS opened at $0.25 on Friday. The firm has a market cap of $2.69 million, a PE ratio of -0.03 and a beta of 1.63. The stock’s fifty day moving average price is $0.53 and its two-hundred day moving average price is $0.67. Ayala Pharmaceuticals has a 1 year low of $0.14 and a 1 year high of $1.95.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last issued its earnings results on Tuesday, April 16th. The company reported ($2.96) earnings per share (EPS) for the quarter.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
See Also
- Five stocks we like better than Ayala Pharmaceuticals
- How to Buy Cheap Stocks Step by Step
- MarketBeat Week in Review – 5/20 – 5/24
- How to Invest in Biotech Stocks
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- These 2 Retail Traders Favorites are Nearing Major Breakouts
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
